<!DOCTYPE html>
<html>
    <head>
        <title>ONALABS QMS : OV G2.2. Post-Market Clinical Follow Up Plan</title>
        <link rel="stylesheet" href="styles/site.css" type="text/css" />
        <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    </head>

    <body class="theme-default aui-theme-default">
        <div id="page">
            <div id="main" class="aui-page-panel">
                <div id="main-header">
                    <div id="breadcrumb-section">
                        <ol id="breadcrumbs">
                            <li class="first">
                                <span><a href="index.html">ONALABS QMS</a></span>
                            </li>
                                                    <li>
                                <span><a href="OV-ONAVITAL-MDR-Product-Technical-File_3342337.html">OV ONAVITAL MDR Product Technical File</a></span>
                            </li>
                                                    <li>
                                <span><a href="3343001.html">OV Part G: Clinical Evaluation, PMS and PMCF</a></span>
                            </li>
                                                    <li>
                                <span><a href="OV-G2.-Post-Market-Surveillance_3343051.html">OV G2. Post Market Surveillance</a></span>
                            </li>
                                                </ol>
                    </div>
                    <h1 id="title-heading" class="pagetitle">
                                                <span id="title-text">
                            ONALABS QMS : OV G2.2. Post-Market Clinical Follow Up Plan
                        </span>
                    </h1>
                </div>

                <div id="content" class="view">
                    <div class="page-metadata">
                            
        
    
        
    
        
        
            Created by <span class='author'> Richard Bunney</span>, last modified by <span class='editor'> Jaime Punter</span> on Jun 06, 2025
                        </div>
                    <div id="main-content" class="wiki-content group">
                    <p><span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">COMPANY CONFIDENTIAL</span> <span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">UNCONTROLLED IF PRINTED</span></p><p>Owner: Jaime Punter, CTO and Quality Representative</p><div class="ap-container" id="ap-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro4568839729347460177">

  <div class="ap-content " id="embedded-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro4568839729347460177"></div>
  <script nonce="528a568c4bd9f0fff5a3a25050ba0fb5" class="ap-iframe-body-script">
  (function(){
    var data = {
    "addon_key":"com.automation-consultants.accloud.approvalmacro",
    "uniqueKey":"com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro4568839729347460177",
    "key":"ApprovalsStatusMacro",
     "moduleType":"dynamicContentMacros",      "moduleLocation":"content",         "cp":"/wiki",
            "general":"",
    "w":"",
    "h":"",
    "url":"https://ac-cloud.com/approvalmacro/macro/page-status/display?xdm_e=https%3A%2F%2Fonalabs.atlassian.net&xdm_c=channel-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro4568839729347460177&cp=%2Fwiki&xdm_deprecated_addon_key_do_not_use=com.automation-consultants.accloud.approvalmacro&lic=active&cv=1000.0.0-c58bc7260813&traceId=33add740a660868b3cff45bb950de831&spanId=1a286229967a5753&traceSampled=0&jwt=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiI2MDU0OTY2Yjk0ZDdiOTAwNjkwMmRkMWUiLCJxc2giOiJlZjBkMzQ4MzViYzVmYWQyYjk0N2NjODc4NDZmYjc1MGE1N2Q5Njk5N2M4YjQ2ODk4MzFiZWY1NzUzYzVkNzYyIiwiaXNzIjoiNzdjODA3YTAtMmNjNy0zZWVjLWEzNDItOWQzYzYyZjUwZWE0IiwiY29udGV4dCI6e30sImV4cCI6MTc1MTI5NjQ0NCwiaWF0IjoxNzUxMjk2MjY0fQ.sHUp2wb864iOrj6QqN6TuyL09_ynQV8y00oeLkx066o",
     "contextJwt": "eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.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.HXOLo37TE3JrBl2HLsi8nEnp-UmZu4Ba-16GHjCKQvM",    "structuredContext": "{\"license\":{\"active\":true},\"confluence\":{\"editor\":{\"version\":\"v2\"},\"macro\":{\"outputType\":\"html_export\",\"hash\":\"cfbe216d-e6ad-4025-a18d-cb42699f2dca\",\"id\":\"cfbe216d-e6ad-4025-a18d-cb42699f2dca\"},\"tracing\":{\"traceId\":\"33add740a660868b3cff45bb950de831\",\"spanId\":\"1a286229967a5753\",\"sampled\":\"0\"},\"content\":{\"type\":\"page\",\"version\":\"9\",\"id\":\"80150529\"},\"space\":{\"key\":\"ONALABSQMS\",\"id\":\"2752512\"}},\"url\":{\"displayUrl\":\"https://onalabs.atlassian.net/wiki\"}}",
    "contentClassifier":"content",
    "productCtx":"{\"page.id\":\"80150529\",\"macro.hash\":\"cfbe216d-e6ad-4025-a18d-cb42699f2dca\",\"space.key\":\"ONALABSQMS\",\"tracing.sampled\":\"0\",\"page.type\":\"page\",\"content.version\":\"9\",\"page.title\":\"OV G2.2. Post-Market Clinical Follow Up Plan\",\"macro.localId\":\"ec91a98b-9a96-468e-94c8-49bea1bbe315\",\"macro.body\":\"\",\": = | RAW | = :\":null,\"space.id\":\"2752512\",\"macro.truncated\":\"false\",\"content.type\":\"page\",\"output.type\":\"html_export\",\"page.version\":\"9\",\"macro.fragmentLocalId\":\"\",\"content.id\":\"80150529\",\"tracing.traceId\":\"33add740a660868b3cff45bb950de831\",\"macro.id\":\"cfbe216d-e6ad-4025-a18d-cb42699f2dca\",\"tracing.spanId\":\"1a286229967a5753\",\"user.isExternalCollaborator\":\"false\",\"editor.version\":\"v2\"}",
    "timeZone":"GB",
    "origin":"https://ac-cloud.com",
    "hostOrigin":"https://onalabs.atlassian.net",
    "sandbox":"allow-downloads allow-forms allow-modals allow-popups allow-popups-to-escape-sandbox allow-scripts allow-same-origin allow-top-navigation-by-user-activation allow-storage-access-by-user-activation",    "pearApp":"true",        "apiMigrations": {
        "gdpr": true
    }
}
;
    if(window.AP && window.AP.subCreate) {
      window._AP.appendConnectAddon(data);
    } else {
      require(['ac/create'], function(create){
        create.appendConnectAddon(data);
      });
    }

    // For Confluence App Analytics. This code works in conjunction with CFE's ConnectSupport.js.
    // Here, we add a listener to the initial HTML page that stores events if the ConnectSupport component
    // has not mounted yet. In CFE, we process the missed event data and disable this initial listener.
    const __MAX_EVENT_ARRAY_SIZE__ = 20;
    const connectAppAnalytics = "ecosystem.confluence.connect.analytics";
    window.connectHost && window.connectHost.onIframeEstablished((eventData) => {
      if (!window.__CONFLUENCE_CONNECT_SUPPORT_LOADED__) {
        let events = JSON.parse(window.localStorage.getItem(connectAppAnalytics)) || [];
        if (events.length >= __MAX_EVENT_ARRAY_SIZE__) {
          events.shift();
        }
        events.push(eventData);
        window.localStorage.setItem(connectAppAnalytics, JSON.stringify(events));
      }
    });

  }());
</script>

</div>
<style type='text/css'>/*<![CDATA[*/
div.rbtoc1751296264904 {padding: 0px;}
div.rbtoc1751296264904 ul {list-style: disc;margin-left: 0px;}
div.rbtoc1751296264904 li {margin-left: 0px;padding-left: 0px;}

/*]]>*/</style><div class='toc-macro rbtoc1751296264904'>
<ul class='toc-indentation'>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-1.ManufacturerContactDetails'>1. Manufacturer Contact Details</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-2.Medicaldevicedescriptionandspecification'>2. Medical device description and specification</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-3.ActivitiesrelatedtoPMCF:Generalandspecificmethodsandprocedures'>3. Activities related to PMCF: General and specific methods and procedures</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-5.Referencetotherelevantpartsofthetechnicaldocumentation'>5. Reference to the relevant parts of the technical documentation</a>
<ul class='toc-indentation'>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-5.1.Clinicalevaluationreport'>5.1. Clinical evaluation report</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-5.2.Riskmanagementfile'>5.2. Risk management file</a></li>
</ul>
</li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-6.Evaluationofclinicaldatarelatingtoequivalentorsimilardevices.'>6. Evaluation of clinical data relating to equivalent or similar devices.</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-7.Referencetoanyapplicablecommonspecifications,harmonizedstandardsorapplicableguidancedocuments.'>7. Reference to any applicable common specifications, harmonized standards or applicable guidance documents.</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-8.PMCFevaluationreport'>8. PMCF evaluation report</a>
<ul class='toc-indentation'>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-8.1PMCFevaluationreporttemplate'>8.1 PMCF evaluation report template</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-8.2EstimateddateofthePMCFevaluationreport'>8.2 Estimated date of the PMCF evaluation report</a></li>
</ul>
</li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-9.Exceptions'>9. Exceptions</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-10.Enforcement'>10. Enforcement</a></li>
<li><a href='#OVG2.2.Post-MarketClinicalFollowUpPlan-11.DocumentDistribution'>11. Document Distribution</a></li>
</ul>
</div><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-1.ManufacturerContactDetails">1. Manufacturer Contact Details</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="57274132-0d50-4e8c-a34e-3ca46b258976" class="confluenceTable"><tbody><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Legal Manufacturer Name:</strong></p></td><td class="confluenceTd"><p>ONALABS INNO-HUB SL</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Address:</strong></p></td><td class="confluenceTd"><p>Avinguda del Parc Tecnologic, 3, Cerdanyola del Vallès, 08290, Barcelona</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>SRN:</strong></p></td><td class="confluenceTd"><p>ES-MF-000043048</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>PRRC:</strong></p></td><td class="confluenceTd"><p>Jaime Punter-Villagrasa</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>E-mail:</strong></p></td><td class="confluenceTd"><p><a class="external-link" href="mailto:j.punter@onalabs.com" rel="nofollow">j.punter@onalabs.com</a></p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Phone:</strong></p></td><td class="confluenceTd"><p>+34 935824418</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Fax:</strong></p></td><td class="confluenceTd"><p>NA</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Authorized Representative:</strong></p></td><td class="confluenceTd"><p>NA</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Address:</strong></p></td><td class="confluenceTd"><p>-</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Contact Person:</strong></p></td><td class="confluenceTd"><p>-</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>E-mail:</strong></p></td><td class="confluenceTd"><p>-</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Phone:</strong></p></td><td class="confluenceTd"><p>-</p></td></tr><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Fax:</strong></p></td><td class="confluenceTd"><p>-</p></td></tr></tbody></table></div><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-2.Medicaldevicedescriptionandspecification">2. Medical device description and specification</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="172fee70-32ef-4bd1-82d3-a19ed489e0fc" class="confluenceTable"><colgroup><col style="width: 199.0px;"/><col style="width: 560.0px;"/></colgroup><tbody><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Product or Trade Name:</strong></p></td><td class="confluenceTd"><p>ONAVITAL</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Model(s) and Type(s):</strong></p></td><td class="confluenceTd"><p>ONAVITAL</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>General description of the device:</strong></p></td><td class="confluenceTd"><p>ONAVITAL by Onalabs Inno-hub SL is a medical-grade device for remote, spot check monitoring of vital signs. ONAVITAL provides accurate and precise measurements of Pulse Rate (PR), Oxygent Saturation (SpO2), Systolic and Diastolic Arterial Blood Pressure (ABP) and Skin-surface Temperature (ST) through a wearable physical bracelet.</p><p>ONAVITAL is intended to be used by patients that are not considered to be in a critical condition.</p><p>ONAVITAL is a wearable physical sensor bracelet worn by the patient/user including sensors and calibration algorithms for vital signs acquisition and adapters for data digitalization.</p><p>The wearable is comprised of a hardware electronic element, encapsulated in a bio-compatible plastic injection casing and a hypoallergenic wrist band.</p><p>The firmware works in real time using an integrated solid memory, multiplexed design of I2C signal input ports, and a serial digital communication system for sensors integrated in the device. The real time capability of the physical sensors and firmware in parallel enables the capture of clinical parameters at the same time as the biometric signals from which they are extracted are acquired.</p><p>In addition to the measurement and signal processing systems, the wearable includes elements for its correct operation: a rechargeable battery and operation commands (for example start, stop, connect). There is memory data storage protocol to avoid its loss in case of disconnection from the communication network and embedded algorithms to be able to process the data obtained from the different sensors. The sensors give a digitized electrical response correlated with different biometric and/or physiological elements. These signals are processed to get more compact data to facilitate their transmission in near real time for sufficient functionality and operability due to the clinical characteristics of its application.</p><p>The device collects data which is then securely transmitted through an associated mobile application to the cloud-based platform.</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Intended Purpose:</strong></p></td><td class="confluenceTd"><p>ONAVITAL by Onalabs Inno-hub SL is a remote monitoring device for spot check collection of accurate measurements of Pulse Rate (PR), Oxygen Saturation (SpO2), Arterial Blood Pressure (ABP) and Skin Temperature (STEMP). ONAVITAL is intended for spot-checking and tracking vital signs of adult patients in general and cardiorespiratory patients in particular. The device is not intended for use on critical care patients.</p><p>It uses photopletismography (PPG) technology to estimate the oxygen saturation of the blood, the pulse rate and systolic and diastolic arterial blood pressure. Skin temperature is measured through a digital thermometer IC. Reflective PPG technology, in which specific wavelengths of light are transmitted onto the skin, and the reflected light is collected by a photodiode detector positioned near the light source transmitter. The sensor tracks vital signs derived from changes in the pulse contour, following a simple offset baseline auto-calibration process using an approved non-invasive, cuff-based device, and is based on Pulse Wave Analysis (PWA)</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Intended Users:</strong></p></td><td class="confluenceTd"><p>Adult patients in general and cardiorespiratory patients in particular</p><p>Patients that are not considered to be in a critical condition</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Basic UDI-DI:</strong></p></td><td class="confluenceTd"><p>84370264941SH</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Intended Patient Population:</strong></p></td><td class="confluenceTd"><p>Adult patients in general and cardiorespiratory patients in particular</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Medical Condition(s):</strong></p></td><td class="confluenceTd"><p>Spot check monitoring of vital signs (accurate and precise measurements of Pulse Rate (PR), Oxygent Saturation (SpO2), Systolic and Diastolic Arterial Blood Pressure (ABP) and Skin-surface Temperature (ST))</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Indications:</strong></p></td><td class="confluenceTd"><p>ONAVITAL is intended for spot-checking and tracking vital signs of adult patients remotely. The data from the ONAVITAL TM is intended for use by patients and healthcare professionals as an aid to diagnosis and treatment. The device is not intended for use on critical care patients.</p><p>ONAVITAL can be used on any location where there is internet connectivity whether they are private residences or other environments such as nursing homes, primary care centres</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Contraindications:</strong></p></td><td class="confluenceTd"><p>People without the skills and competencies to operate the digital solution.</p><p>Pulse oximeters have limitations and a risk of inaccuracy under certain circumstances. In many cases, the level of inaccuracy may be small and not clinically meaningful; however, there is a risk that an inaccurate measurement may result in unrecognized low oxygen saturation levels.</p><p>The SpO2 reading should always be considered an estimate of oxygen saturation. For example, if a pulse oximeter reads 90%, then the true oxygen saturation in the blood is generally between 86-94%. Pulse oximeter accuracy is highest at saturations of 90-100%, intermediate at 80-90%, and lowest below 80%.</p><p>Due to accuracy limitations at the individual level, SpO2 provides more utility for trends over time instead of absolute thresholds.</p><p>Many patient factors may also affect the accuracy of the measurement. The most current scientific evidence shows that there are some accuracy differences in pulse oximeters between dark and light skin pigmentation; this difference is typically small at saturations above 80% and greater when saturations are less than 80%.</p><p>Wireless pulse oximeters do not have unlimited range. To work effectively the wireless oximeter must be in Bluetooth range of the device they are communicating with.</p><p>Do not use with neonatal patients.</p><p>If the device is mechanically damaged it must not be used and must be disposed.</p><p>The device have been designed and evaluated to be used in adults, do not use on paediatrics.</p><p>Do not use with patients with significant deformity, swelling, irritation, degenerative changes or edema of<br/>the wrist.</p><p>Do not use the wrist monitor on patients with localized infection, ulceration or skin lesions involving the wrist.</p><p>Do not use the wrist monitor on patients that have restricted blood flow e.g. tourniquet, pressure cuff or IV line.</p><p>Do not use with patients with tremors or convulsions.</p><p>Do not use with patients with peripheral vascular disease affecting the hands.</p><p>Do not use on an area with a tattoo.</p><p>DO NOT use in MRI or a CT environment.</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Precautions:</strong></p></td><td class="confluenceTd"><p>Disposal of this device should be performed in accordance with local regulations.</p><p>Do not disassemble any part of the system components.</p><p>This system is not user-serviceable.</p><p>Use the device only for the purpose described in the indications for use.</p><p>Do not use accessories which are not supplied or recommended by the manufacturer.</p><p>Do not use the device if it is not working properly or if it has suffered any damage, for example, a damaged casing, or damage caused by dropping the equipment or immersing it in water or other liquids. Stop using the device and contact the manufacturer.</p><p>The device is designed to determine the percentage of arterial oxygen saturation of functional hemoglobin. Factors that may degrade performance or affect the accuracy of the measurement include the following:</p><p>Device not applied correctly</p><p>Excessive motion</p><p>Intravascular dyes</p><p>Avoid too much light such as sunlight or bright indoor lighting.</p><p>The device has no audible alarms and is intended for periodic spot checking.</p><p>The wrist-monitor may not work when circulation is reduced. Warm or rub the wrist area to increase<br/>perfusion.</p><p>The device does not require cleaning on a routine basis. However, if the outer surface of the device is not clean, it may be cleaned with a soft, lint-free cloth moistened by ethyl alcohol (70-85%) until visually clean.</p><p>Do not sterilize, autoclave, or immerse this device in liquid.</p><p>This device is a precision electronic instrument and must be repaired by Onalabs Inno-Hub SL qualified technical professionals. Field repair of the device is not possible. Do not attempt to open the case or repair the electronics. Opening the case may damage the device and void the warranty.</p><p>The equipment complies with IEC60601-1-2 for electromagnetic compatibility for medical electrical<br/>equipment and / or systems. This standard is designed to provide reasonable protection against harmful<br/>interference in a typical medical installation. However, because of the proliferation of radio frequency<br/>transmitting equipment and other sources of electrical noise in health care and other environments, it is possible that high levels of interference due to close proximity or strength of a source might disrupt the some of the features of this device.</p><p>Portable and mobile RF communications equipment including CT, MRI, diathermy, RFID, and electronic<br/>article security systems can affect medical electrical equipment.</p><p>Follow local, state, and national governing ordinances and recycling instructions regarding disposal or recycling of the device and device components, including batteries.</p><p>In compliance with the European Directive on Waste for Electrical and Electronic equipment (WEEE) 2002/96/ EC, do not dispose of this product as unsorted municipal waste. This device contains WEEE materials; please contact your distributor regarding return or recycling of the device.</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Warnings:</strong></p></td><td class="confluenceTd"><p>Real-world accuracy may differ from accuracy in the lab setting. While reported accuracy is an average of all patients in the test sample, there are individual variations among patients. The SpO<sub>2</sub> reading should always be considered an <em>estimate</em> of oxygen saturation. For example, if a pulse oximeter reads 90%, then the true oxygen saturation in the blood is generally between 86-94%. Pulse oximeter accuracy is highest at saturations of 90-100%, intermediate at 80-90%, and lowest below 80%.</p><p>The SPO2 and ABP vital signs are highly sensitive to the location of the device on the patient and any movement from the patient. ONAVITAL have an embedded analyser for these eventualities so if any measurement is influenced by placement or movement, ONAVITAL is going to discard these measurements for safety reasons.</p><p>ONAVITAL is MR Unsafe.</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>List and description of any variants and/or configurations covered by this plan:</strong></p></td><td class="confluenceTd"><p /><div class="table-wrap"><table data-layout="default" data-local-id="9225d13f-978a-4cca-b720-e20097e8dbdd" class="confluenceTable"><tbody><tr><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Product name</strong></p></td><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Trade name</strong></p></td><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Internal reference</strong></p></td><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Basic</strong></p><p><strong>UDI-DI</strong></p></td><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>UDI-DI</strong></p></td><td data-highlight-colour="#d9d9d9" class="confluenceTd"><p><strong>Variant</strong></p></td></tr><tr><td class="confluenceTd"><p>ONAVITAL</p><p>v3</p></td><td class="confluenceTd"><p>ONAVITAL</p></td><td class="confluenceTd"><p>ONAVITAL v3</p></td><td class="confluenceTd"><p>84370264941SH</p></td><td class="confluenceTd"><p>8437026494001</p></td><td class="confluenceTd"><p>Single variant</p></td></tr></tbody></table></div><p> </p><p> </p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>List of any accessories covered by this plan:</strong></p></td><td class="confluenceTd"><p>Charging cable. The magnetic charge cable is used for ONAVITAL battery charging</p><p>Reset pin. The reset pin is used to activate the inner button of the device for different functions explained on the user manual.</p><p>IOS and Android apps for visualisation. The application enables users to visualise the data captured by the wearable component.</p><p>Cloud based platform used to collect and throughput data from the wearable bracelet to the mobile application for visualisation. Data from the wearable is securely transmitted via an associated mobile phone to a cloud-based platform for storage and visualisation. Data securely held on the platform is then displayed by the mobile application to an individual user, or can be collated into summary dashboards or shared via APIs. The platform functions as a medical device data system and is used to manage authentication and associate device data with registered individuals.</p><p>IOS and Android apps for visualisation. The application enables users to visualise the data captured by the wearable component.</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Certificate Number (if available):</strong></p></td><td class="confluenceTd"><p>Non available (certificate pending)</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>EMDN:</strong></p></td><td class="confluenceTd"><p>C900301 Cardiocirculatory devices - Pulse oximeter sensors</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Class:</strong></p></td><td class="confluenceTd"><p>Class IIb</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Classification Rule:</strong></p></td><td class="confluenceTd"><p>Rule 10</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Expected Lifetime:</strong></p></td><td class="confluenceTd"><p>4 years</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Novel Product:</strong></p></td><td class="confluenceTd"><p> <strong>☒</strong> YES    <strong>☐</strong> NO</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Novel related clinical procedure:</strong></p></td><td class="confluenceTd"><p> <strong>☐</strong> YES    <strong>☒</strong> NO</p></td></tr><tr><td data-highlight-colour="#f4f5f7" class="confluenceTd"><p><strong>Explanation of any novel features:</strong></p></td><td class="confluenceTd"><p /></td></tr></tbody></table></div><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-3.ActivitiesrelatedtoPMCF:Generalandspecificmethodsandprocedures">3. Activities related to PMCF: General and specific methods and procedures</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="1abb4dab-2919-4259-84c6-4e311aa888ec" class="confluenceTable"><tbody><tr><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>ID #</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>General &amp; Specific methods and Procedures (Description of activity)</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Aim of the activity</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Rationale for method and procedure appropriateness</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Frequency/timeline</strong></p></th></tr><tr><td class="confluenceTd"><p><strong>PMCF01*</strong></p><p><strong>(PMS02)</strong></p></td><td class="confluenceTd"><p><strong>General method - Periodic search of scientific literature and other sources</strong>.</p><p>Conduct literature search according to the specified state of the art and/ or establishment of clinical evidence of the device for the scientific-technical evaluation of:</p><p>· Scientific literature and clinical research data reviews</p><p>· Bibliographic reviews of data relating to similar devices on the market</p><p>· Publicly available information about similar/ equivalent medical devices</p><p>· Adverse event databases may contain information regarding events that have occurred for similar medical devices.</p></td><td class="confluenceTd"><p>· Confirming the clinical performance data relating to similar devices, and the current state of the art. Verify that clinical claims are met</p><p>· Confirming the clinical safety of the device</p><p>· Identify possible systematic misuse or off-label uses of the device, unknown-side effects, and contraindications</p><p>· Identify and analyse emergent risks</p><p>· Ensuring the continued acceptability of the benefit-risk ratio</p></td><td class="confluenceTd"><p>This method will provide the relevant scientific information on the devices identified as per the same clinical claims and the novelties for intended patient group of the device under evaluation.</p><p>This method will also provide information on similar devices/state of the art</p></td><td class="confluenceTd"><p>Yearly review of new, relevant clinical data is compiled in the PSUR &amp; PMCF evaluation report.</p></td></tr><tr><td class="confluenceTd"><p><strong>PMCF02*</strong></p><p><strong>(PMS04)</strong></p></td><td class="confluenceTd"><p><strong>General method - Customer feedback- Reactive actions.</strong></p><p>Assessment of information from:</p><p>· Customer/ distributor complaints data</p><p>· Other sources of non-expected events</p><p>Control of:</p><p>· Trend reporting</p></td><td class="confluenceTd"><p>· Confirming the clinical safety of the device</p><p>· Identify possible systematic misuse or off-label uses of the device, unknown-side effects, and contraindications</p><p>· Identify and analyse emergent risks</p></td><td class="confluenceTd"><p>These methods will raise potential issues experienced by product users</p></td><td class="confluenceTd"><p>Ongoing data collection.</p><p> </p><p>Yearly review of new, relevant clinical data is compiled in the PSUR &amp; PMCF report.</p></td></tr><tr><td class="confluenceTd"><p><strong>PMCF03*</strong></p><p><strong>(PMS05)</strong></p></td><td class="confluenceTd"><p><strong>General method - Customer feedback- Proactive actions.</strong></p><p>Assessment of information from:</p><p>· Surveys data (survey from patients/ users)</p><p> </p></td><td class="confluenceTd"><p>· Confirming the clinical performance data relating to similar devices, and the current state of the art. Verify that clinical claims are met</p><p>· Confirming the clinical safety of the device</p><p>· Identify possible systematic misuse or off-label uses of the device, unknown-side effects, and contraindications</p><p>· Identify and analyse emergent risks</p><p>· Ensuring the continued acceptability of the benefit-risk ratio</p></td><td class="confluenceTd"><p>This method will raise potential issues experienced by product users</p><p> </p><p>This method will identify valuable information from clinical performance of the device.</p></td><td class="confluenceTd"><p>Ongoing data collection.</p><p> </p><p>Yearly review of new, relevant clinical data is compiled in the PSUR &amp; PMCF report.</p></td></tr></tbody></table></div><p><strong>*</strong> <strong>These PMCF inputs are shared within PMCF Plan and PMS plan. This information may be extracted from the PSUR data or can be utilised in both PMCF report and PSUR.</strong></p><p>No specific methods and procedures of PMCF were included due to the following reasons:</p><ul><li><p>The clinical evaluation includes sufficient clinical data to support the claims;</p></li><li><p>The long-term safety and performance of the technology is known;</p></li><li><p>The risk-benefit ratio of the product is acceptable.</p></li></ul><p>Therefore, we consider that the general methods and procedures included in this PMCF, together with the clinical evaluation, risk management analysis and the post-market surveillance activities, provide enough evidence to support the clinical safety of ONAVITAL.</p><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-5.Referencetotherelevantpartsofthetechnicaldocumentation">5. Reference to the relevant parts of the technical documentation</h3><p>In this section is included references to the relevant information from clinical evaluation report and from the risk management file, which need to be analysed, followed up, and evaluated in this plan.</p><p>As an alternative, is required to state that there is no relevant information from the clinical evaluation report and/or from the risk management file to be considered in this plan.</p><h4 id="OVG2.2.Post-MarketClinicalFollowUpPlan-5.1.Clinicalevaluationreport">5.1.   Clinical evaluation report</h4><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="3c24c430-444c-458d-aff8-39ce128c10c7" class="confluenceTable"><tbody><tr><td class="confluenceTd"><p><strong>☒</strong></p></td><td class="confluenceTd"><p><strong>No relevant information from performance evaluation report to be considered in this plan.</strong></p><p>The main clinical risks (clinically relevant hazard situations) have been considered within the clinical evaluation report. These risks are included for ongoing monitoring and analysis according to the PMS Plan (<em>OV G2.1. Post-Market Surveillance Plan ONAVITAL</em>) as well as in this PMCF Plan.</p></td></tr><tr><td class="confluenceTd"><p><strong>☐</strong></p></td><td class="confluenceTd"><p>Relevant information to be further analyzed and monitored:</p><p><em>N/A</em></p></td></tr></tbody></table></div><h4 id="OVG2.2.Post-MarketClinicalFollowUpPlan-5.2.Riskmanagementfile">5.2.   Risk management file</h4><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="404b8053-0608-4ae5-b886-a875358a329d" class="confluenceTable"><tbody><tr><td class="confluenceTd"><p><strong>☒</strong></p></td><td class="confluenceTd"><p><strong>No relevant information from risk management report to be considered in this plan</strong></p><p>This risk management process is documented in the technical documentation of the device under evaluation. The risk reduction (application of the measures for the mitigation, control or reduction of the risks identified) process is undertaken to reduce the risks of the device as far as possible, without adverse effects on the benefit-risk ratio.</p><p>In addition, all risks are documented and managed. Specific tasks are planned for ongoing monitoring and analysis according to the PMS Plan (<em>OV G2.1. Post-Market Surveillance Plan ONAVITAL</em>) as well as in this PMCF Plan.</p></td></tr><tr><td class="confluenceTd"><p><strong>☐</strong></p></td><td class="confluenceTd"><p>Relevant information to be further analyzed and monitored:</p><p><em>N/A</em></p></td></tr></tbody></table></div><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-6.Evaluationofclinicaldatarelatingtoequivalentorsimilardevices.">6. Evaluation of clinical data relating to equivalent or similar devices.</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="cf1daef4-dbf4-4a9d-bf08-21398aecf2c1" class="confluenceTable"><tbody><tr><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Product name of equivalent / similar</strong></p><p><strong>device</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Intended purpose</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Intended users</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Intended patient population</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Medical condition/ Indications</strong></p></th><th data-highlight-colour="#f4f5f7" class="confluenceTh"><p><strong>Reference to clinical</strong></p><p><strong>data evaluation</strong></p></th></tr><tr><td class="confluenceTd"><p>BB-613WP</p><p>(Bio-Beat)</p></td><td class="confluenceTd"><p>To monitor Pulse Rate, SpO2, Respiratory rate, Blood pressure, Mean arterial pressure Cardiac index Cardiac output Heart rate variability Systemic vascular resistance, Pulse pressure, Skin temperature, Sweat level. Intended to be used in hospitals, clinics, long-term care, and home use.</p></td><td class="confluenceTd"><p>Non-critical adult patients and qualified medical personnel.</p></td><td class="confluenceTd"><p>General use</p></td><td class="confluenceTd"><p>Potential findings by means of interpretation of provided data by a qualified medical professional. Not diagnostics.</p></td><td class="confluenceTd"><p>OV A1.7. Similar Devices</p></td></tr><tr><td class="confluenceTd"><p>Bora-Band BB-100 (Biosency)</p></td><td class="confluenceTd"><p>To monitor Pulse Rate, SpO₂, Blood Pressure and Skin Temperature for use at home, outdoors, and within medical settings.</p></td><td class="confluenceTd"><p>Non-critical adult patients and qualified medical personnel</p></td><td class="confluenceTd"><p>General use and chronic respiratory diseases.</p></td><td class="confluenceTd"><p>To detect nocturnal desaturations, to identify an incorrect oxygen therapy<br/>prescription and generate a new O2 prescription and/or order another test, and to prevent<br/>readmission after hospital discharge.</p></td><td class="confluenceTd"><p>OV A1.7. Similar Devices</p></td></tr><tr><td class="confluenceTd"><p>Cardio Watch 287-2B (Corsano Health)</p></td><td class="confluenceTd"><p>To continuously monitor physiological vital sign data (Pulse Rate (PR), oxygen saturation (SpO2), body temperature (TEMP), blood pressure (NIBP) and activity levels (MOTION / STEP) for use in professional healthcare facilities, such as hospitals or skilled nursing facilities, or the home.</p></td><td class="confluenceTd"><p>Qualified medical personnel only. Single patient use under supervision.</p></td><td class="confluenceTd"><p>General use</p></td><td class="confluenceTd"><p>Potential findings by means of interpretation of provided data by a qualified medical professional. No diagnostics.</p></td><td class="confluenceTd"><p>OV A1.7. Similar Devices</p></td></tr><tr><td class="confluenceTd"><p>Bracelet G1 (Aktiia)</p></td><td class="confluenceTd"><p>To monitor of Pulse Rate and Blood Pressure in home use only.</p></td><td class="confluenceTd"><p>Non-critical adult patients and qualified medical personnel</p></td><td class="confluenceTd"><p>General use and patients in need of ambulatory blood pressure monitoring</p></td><td class="confluenceTd"><p>Potential findings by means of interpretation of provided data by a qualified medical professional. Clinical benefit of a long-term unbiased blood pressure and heart rate monitoring. This clinical benefit to the user stems from the acceptable accuracy, stability and automaticity of the blood pressure and heart rate estimation in compliance with the requirements of the relevant standards.</p></td><td class="confluenceTd"><p>OV A1.7. Similar Devices</p></td></tr></tbody></table></div><p /><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-7.Referencetoanyapplicablecommonspecifications,harmonizedstandardsorapplicableguidancedocuments.">7. Reference to any applicable common specifications, harmonized standards or applicable guidance documents.</h3><p>The main legislation and guidance applicable to this PMCF plan are listed in the table below. There is no common specification applicable to the device under evaluation.</p><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="11e26a5d-25f7-45d4-acb6-3594f8726306" class="confluenceTable"><tbody><tr><td data-highlight-colour="#767171" class="confluenceTd"><p><strong>Document</strong></p></td><td data-highlight-colour="#767171" class="confluenceTd"><p><strong>Description</strong></p></td></tr><tr><td class="confluenceTd"><p>Regulation (EU) 2017/745</p></td><td class="confluenceTd"><p>Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (and its amendments)</p></td></tr><tr><td class="confluenceTd"><p>MDCG 2020-7</p></td><td class="confluenceTd"><p>Post-market clinical follow-up (PMCF) Plan Template. A guide for manufacturers and notified bodies</p></td></tr><tr><td class="confluenceTd"><p>MDCG 2020-5  </p></td><td class="confluenceTd"><p>Guidance on clinical evaluation – Equivalence</p></td></tr></tbody></table></div><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-8.PMCFevaluationreport">8. PMCF evaluation report</h3><h4 id="OVG2.2.Post-MarketClinicalFollowUpPlan-8.1PMCFevaluationreporttemplate">8.1 PMCF evaluation report template</h4><p class="media-group"><span class="confluence-embedded-file-wrapper"><a class="confluence-embedded-file" href="attachments/80150529/995065871.docx" data-nice-type="Microsoft Word Document" data-file-src="/wiki/download/attachments/80150529/NC9_PMCF%20Report_template%20semifull.docx?version=1&amp;modificationDate=1749204544363&amp;cacheVersion=1&amp;api=v2" data-linked-resource-id="995065871" data-linked-resource-type="attachment" data-linked-resource-container-id="80150529" data-linked-resource-default-alias="NC9_PMCF Report_template semifull.docx" data-mime-type="application/vnd.openxmlformats-officedocument.wordprocessingml.document" data-has-thumbnail="true" data-linked-resource-version="1" data-media-id="e53ab90e-fc29-4acd-99f2-5453ff01ce8d" data-media-type="file"><img src="attachments/thumbnails/80150529/995065871" height="250"/></a></span></p><h4 id="OVG2.2.Post-MarketClinicalFollowUpPlan-8.2EstimateddateofthePMCFevaluationreport">8.2 Estimated date of the PMCF evaluation report</h4><p>An PMCF evaluation report shall be created every year after the CE certification of the device even in the absence of significant changes.</p><p>In this report (according to MDCG 2020-8), Onalabs Inno-Hub SL will collect and analyse all relevant data from general and specific methods as set out in this PMCF Plan.</p><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-9.Exceptions">9. Exceptions</h3><p>There are no exceptions to this plan except by senior management sign off . </p><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-10.Enforcement">10. Enforcement</h3><p>OnaLabs sl will perform regular audits to ensure policy compliance in accordance with the Internal Audit Standard Operating Procedure. Non-compliance will be escalated to business management. </p><h3 id="OVG2.2.Post-MarketClinicalFollowUpPlan-11.DocumentDistribution">11. Document Distribution</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="bff8e683-bf7d-4399-8729-13095316e7b1" class="confluenceTable"><colgroup><col style="width: 380.0px;"/><col style="width: 380.0px;"/></colgroup><tbody><tr><td class="confluenceTd"><p>Group</p></td><td class="confluenceTd"><p>Action/ information</p></td></tr><tr><td class="confluenceTd"><p>This document is intended for an internal and (restricted) external audience.</p><p>The external audience may include the following organisations and regulators:</p><ul><li><p>Approved Bodies: conformity assessment bodies for the Medical Device Regulations.</p></li><li><p>Certification Body responsible for auditing and certifying the Quality Management System (QMS) to ISO 13485 </p></li><li><p>Third party contractors and suppliers involved in the manufacture</p></li></ul><p>All external distribution of this document must be approved prior to circulation.</p></td><td class="confluenceTd"><p>Information</p><p> </p></td></tr></tbody></table></div><p> </p>
                    </div>

                                        <div class="pageSection group">
                        <div class="pageSectionHeader">
                            <h2 id="attachments" class="pageSectionTitle">Attachments:</h2>
                        </div>

                        <div class="greybox" align="left">
                                                            <img src="images/icons/bullet_blue.gif" height="8" width="8" alt=""/>
                                <a href="attachments/80150529/995065871.docx">NC9_PMCF Report_template semifull.docx</a> (application/vnd.openxmlformats-officedocument.wordprocessingml.document)
                                <br/>
                                                    </div>
                    </div>
                    
                                                      
                </div>             </div> 
            <div id="footer" role="contentinfo">
                <section class="footer-body">
                    <p>Document generated by Confluence on Jun 30, 2025 16:11</p>
                    <div id="footer-logo"><a href="http://www.atlassian.com/">Atlassian</a></div>
                </section>
            </div>
        </div>     </body>
</html>
